Loading blog post…
A complete guide to post-inflammatory hyperpigmentation (PIH) — how inflammation triggers melanocyte overactivation producing excess melanin in the epidermis (epidermal PIH) or dermis (dermal PIH), why darker skin types are disproportionately affected, the evidence-based treatment hierarchy (sun protection first, then tranexamic acid, niacinamide, kojic acid, azelaic acid, and vitamin C), how to distinguish epidermal from dermal PIH using the Wood's lamp test, the role of retinoids in accelerating resolution, what makes PIH worse, and realistic timelines for clearing.
· By MedSpot Editorial · 5 min read
Post-inflammatory hyperpigmentation is the most common pigmentation concern across all skin types — and one of the most frustrating to treat because the underlying mechanics are often misunderstood. Here is the complete evidence-based guide.
PIH results from an abnormal melanocyte response to skin inflammation. The cascade:
Key point: PIH is not caused by the original insult directly — it is caused by the inflammatory response to it. Minimizing inflammation (from any cause) is the most important PIH prevention strategy.
| Feature | Epidermal PIH | Dermal PIH |
|---|---|---|
| Melanin location | Upper epidermis | Papillary and reticular dermis |
| Color | Brown, tan | Grey, blue-grey, ashen |
| Wood's lamp | Accentuates (appears darker) | Does not accentuate |
| Response to topicals | Responds well | Poor response to topicals |
| Timeline | Months | Years to permanent |
| Treatment | Topical depigmenting agents + retinoids | Laser (Q-switched Nd:YAG, picosecond) |
The Wood's lamp test: A UV lamp that accentuates epidermal melanin (makes brown spots appear much darker) but does not accentuate dermal melanin (grey spots look the same). This is the clinical tool for distinguishing epidermal from dermal PIH — determining whether topical treatment or laser is indicated.
Melanocytes in Fitzpatrick IV–VI skin produce more melanin basally and respond to the same inflammatory stimulus with a more robust melanin surge than in lighter skin types. The melanocytes are not overactive in resting state — they are hyperresponsive to inflammatory triggers. This means:
UV exposure stimulates melanin synthesis independently — it simultaneously darkens existing PIH and prevents topical treatments from working. Every active depigmenting agent on earth is working against UV-induced melanogenesis if SPF is not applied daily.
SPF 30–50+ every morning, regardless of whether the patient goes outside. UVA penetrates glass windows; indoor exposure sustains PIH.
Tinted mineral sunscreen (with iron oxides) provides an additional benefit: it blocks visible light (HEV), which also stimulates melanogenesis in darker skin types — an effect that chemical and untinted mineral filters do not address.
PAR-2 pathway inhibition — addresses the keratinocyte-melanocyte signaling crosstalk that drives post-inflammatory melanocyte overstimulation. 2–5% topical, twice daily. Excellent tolerability across all Fitzpatrick types — no PIH risk from the active itself.
Melanosome transfer inhibition — does not reduce melanin production but prevents its transfer to keratinocytes, reducing visible pigmentation. Highly compatible as a base layer or combination ingredient. Complementary mechanism to tranexamic acid.
Selective cytotoxicity to hyperactive melanocytes. Particularly valuable for PIH in darker skin types — it specifically targets abnormal melanocyte activity without affecting normally active melanocytes, reducing PIH risk from the treatment itself. Prescription formulations preferred for therapeutic effect.
Tyrosinase copper chelation. Effective but with sensitization risk (1–10%) — if sensitization occurs, substitute tranexamic acid or azelaic acid.
Dopaquinone reduction and antioxidant activity. Morning application while the skin is protected by SPF is the standard integration. Lower standalone potency for established PIH than the above agents, but important for combined prevention + treatment.
Do not directly inhibit melanin synthesis, but accelerate epidermal cell turnover — melanin-containing keratinocytes shed faster, clearing epidermal PIH more rapidly than without retinoid use. Also reduce new PIH formation by normalizing follicular hyperkeratinization. Add retinoid to any PIH regimen as an accelerant.
Retinoid caution in darker skin: Retinoid irritation can trigger new PIH in Fitzpatrick IV–VI skin. Start at low concentration (tretinoin 0.025% or retinol 0.025–0.05%), advance slowly, and combine with niacinamide to reduce irritation.
Epidermal PIH: With consistent daily SPF + active depigmenting regimen, most cases show meaningful improvement in 8–12 weeks; complete clearance in 3–6 months.
Dermal PIH: Does not respond to topical agents. Laser treatment (Q-switched Nd:YAG 1064 nm is the most Fitzpatrick-safe) can reduce dermal PIH over multiple sessions (4–8 treatments spaced 4–6 weeks apart). Some dermal PIH is permanent without laser.
Looking for a hyperpigmentation treatment consultation? Browse med spa providers on MedSpot →